<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="80754">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02094547</url>
  </required_header>
  <id_info>
    <org_study_id>FC0G - 010</org_study_id>
    <nct_id>NCT02094547</nct_id>
  </id_info>
  <brief_title>A Neurocognitive and Immunological Study of a New Formula for Healthy Infants</brief_title>
  <acronym>COGNIS</acronym>
  <official_title>Evaluación Del Efecto de Una Nueva fórmula Infantil Con Ingredientes específicos Sobre el Desarrollo Neurocognitivo e inmunológico en Lactantes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Laboratorios Ordesa</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Laboratorios Ordesa</source>
  <oversight_info>
    <authority>Spain: Ethics Committee</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To compare the neurocognitive and immunological development in infants fed a new infant
      formula with functional specific nutrients to infants consuming a standard infant formula.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>December 2010</start_date>
  <completion_date type="Anticipated">December 2014</completion_date>
  <primary_completion_date type="Anticipated">September 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)</study_design>
  <primary_outcome>
    <measure>Neurocognitive Development</measure>
    <time_frame>At 2nd, 3rd, 4th, 6th, 12th and 18th months</time_frame>
    <safety_issue>No</safety_issue>
    <description>Differences in neurocognitive development inter and intragroup evaluated by visual evoked potential test, general movements test, BAYLEY'S III test, Hempel test and cognitive evoked potential test (EEG/ERP).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Tolerability</measure>
    <time_frame>At 2nd, 3rd, 4th, 6th, 12th and 18th months</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Evaluation of gastrointestinal symptoms and sleep disorders amongst groups.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Growth</measure>
    <time_frame>At 2nd, 3rd, 4th, 6th, 12th and 18th months</time_frame>
    <safety_issue>No</safety_issue>
    <description>Differences in growth parameters (weight, length, BMI, skin folds, perimeters and z-scores) between groups.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of infections</measure>
    <time_frame>At 2nd, 3rd, 4th, 6th, 12th and 18th months</time_frame>
    <safety_issue>No</safety_issue>
    <description>Number of infections reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immunoglobulin A secretor (IgAs) levels</measure>
    <time_frame>At 3rd, 6th, 12th and 18th months</time_frame>
    <safety_issue>No</safety_issue>
    <description>Inter and intragroup differences measured by saliva samples analysis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Impact on microbiota</measure>
    <time_frame>At 3rd, 6th, 12th and 18th months</time_frame>
    <safety_issue>No</safety_issue>
    <description>Changes in microbiota composition measured by real-time polymerase chain reaction (RT-PCR) in faeces.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Long Chain Polyunsaturated Fatty Acids (LC-PUFAS) levels</measure>
    <time_frame>At 3rd, 6th, 12th and 18th months</time_frame>
    <safety_issue>No</safety_issue>
    <description>Differences in LC-PUFAS levels inter and intragroup evaluated by oral mucosa samples analysis.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Dietary assessment</measure>
    <time_frame>At 6th, 12th and 18th months</time_frame>
    <safety_issue>No</safety_issue>
    <description>Food frequency questionnaires and 24 h food recalls.</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">170</enrollment>
  <condition>Infant Development</condition>
  <arm_group>
    <arm_group_label>New infant formula</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>New infant formula with key ingredients.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Standard infant formula</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Standard infant formula</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>New infant formula</intervention_name>
    <description>New infant formula</description>
    <arm_group_label>New infant formula</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Standard infant formula</intervention_name>
    <description>Standard infant formula</description>
    <arm_group_label>Standard infant formula</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Full-term newborns (&gt;37 weeks and &lt;41 weeks gestation)

          -  Adequate birth weight for his gestational age (between 3-97 percentiles)

          -  Inclusion age: from 0 to 2 months (60 days)

          -  Maximum 30 days of exclusive breastfeeding

          -  From 30 days on, exclusive or &gt;70% infant formula

          -  Normal Apgar score: 7-10

          -  Umbilical pH ≥ of 7.10

          -  Availability to continue during the whole study period

          -  Informed consent signed ( parent/legal representative)

        Exclusion Criteria:

          -  Participating in other studies.

          -  Nervous system disorders (hydrocephalic, perinatal hypoxia, intraventricular
             hemorrhage, neonatal meningitis, septic shock, West Sd...).

          -  Gastrointestinal disorders (cow's milk protein allergy, lactose intolerance)

          -  Mother's disease history or during pregnancy: neurological and metabolic diseases,
             diabetes mellitus type 1, hypothyroidism, undernutrition, infections TORCH complex.

          -  Mothers receiving anxiolytic or antidepressant treatment during pregnancy or other
             potentially harmful drug treatments for infants' neurodevelopment.

          -  Infant currently participating in another clinical study

          -  Infant's family who in the investigators assessment cannot be expected to comply with
             the protocol.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>60 Days</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Cristina Campoy, Professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Universidad de Granada</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Facultad de Medicina</name>
      <address>
        <city>Granada</city>
        <zip>18071</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>March 2014</verification_date>
  <lastchanged_date>March 21, 2014</lastchanged_date>
  <firstreceived_date>March 20, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Infant Formula</keyword>
  <keyword>Cognition</keyword>
  <keyword>Neurodevelopment</keyword>
  <keyword>Immunity</keyword>
  <keyword>Microbiota</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
